| Product Unit Size | Cost | Quantity | Stock |
|---|
Tranexamic acid is clinically used to decrease blood loss in cardiac surgery and trauma; it inhibits plasmin/plasminogen. In vivo, tranexamic acid inhibits fibrinolysis, decreases bleeding time, and increases thrombus formation. Additionally, tranexamic acid accelerates skin barrier recovery and upregulates occluding expression in UV-damaged skin.
| Cas No. | 1197-18-8 |
|---|---|
| Purity | ≥98% |
| Formula | C8H15NO2 |
| Formula Wt. | 157.21 |
| Chemical Name | Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans- |
| IUPAC Name | 4-(aminomethyl)cyclohexane-1-carboxylic acid |
| Synonym | Tranexan, Tranex, Transamin, Hexatron, Spiramin, Rikavarin, Ugurol, Trasamlon. |
| Melting Point | 386-392°C |
| Solubility | Soluble in water(125mg/mL). Very slightly soluble in alcohol, DMSO or ether. |
| Appearance | White crystalline powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Yuan C, Wang XM, Yang LJ, et al. Tranexamic acid accelerates skin barrier recovery and upregulates occludin in damaged skin. Int J Dermatol. 2013 Aug 22. [Epub ahead of print]. PMID: 23967870.
Sperzel M, Huetter J. Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8. PMID: 17666018.
